A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of PNEUMOSTEM for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia in Premature Infants
Latest Information Update: 17 Mar 2023
At a glance
- Drugs Mesenchymal stem cell therapy Medipost (Primary)
- Indications Bronchopulmonary dysplasia
- Focus Therapeutic Use
- Sponsors Medipost
- 13 Mar 2023 Planned End Date changed from 1 Jul 2021 to 1 Mar 2024.
- 13 Mar 2023 Planned primary completion date changed from 1 Jun 2021 to 1 Dec 2023.
- 26 Feb 2019 Status changed from not yet recruiting to recruiting.